Back to Search
Start Over
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
- Source :
-
Acta Neuropathologica . Nov2023, Vol. 146 Issue 5, p777-781. 5p. - Publication Year :
- 2023
-
Abstract
- Aducanumab is one example of a class of amyloid-targeting antibodies proposed as treatment for early AD [[4], [9]], but few clinicopathological studies are available from patients given these treatments. Keywords: Alzheimer's disease; Amyloid; Lewy body disease; Aducanumab; Clinicopathological correlation EN Alzheimer's disease Amyloid Lewy body disease Aducanumab Clinicopathological correlation 777 781 5 10/12/23 20231101 NES 231101 Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00401-023-02631-8. The extensive tau neurofibrillary pathology suggests that either insufficient amyloid-lowering was achieved initially (remaining > 25 CL) or that tau spreading and propagation continue after amyloid-lowering unless maintenance dosing is administered. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00016322
- Volume :
- 146
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Acta Neuropathologica
- Publication Type :
- Academic Journal
- Accession number :
- 172893898
- Full Text :
- https://doi.org/10.1007/s00401-023-02631-8